🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ezra Y. Rosen

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0002-5289-1541

Also affiliated with Kettering University

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib”.

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278
N/A
0.724DataRank · unranked
124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Characterization of on-target adverse events caused by TRK inhibitor therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.05.006
N/A
0DataRank · unranked
86 citations

James Flory, Andrew Lin, Michael Offin, Christina J. Falcon, Yonina R. Murciano‐Goroff +16 more

BRCA reversion mutations in a pan-cancer cohort to reveal BRCA-dependence in select noncanonical BRCA-mutant histologies.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3012
N/A
0DataRank · unranked
0 citations

Alison M. Schram, Ezra Y. Rosen, Yelena Y. Janjigian, Michael F. Berger, Mark T.A. Donoghue +3 more

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature Communications(2022)10.1038/s41467-022-28848-x
N/A
0DataRank · unranked
114 citations

Helen Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong +27 more

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

Nature Communications(2022)10.1038/s41467-022-34109-8
N/A
0DataRank · unranked
56 citations

Alison M. Schram, Ezra Y. Rosen, Helen Won, Yixiao Gong, Anne Marie Noronha +11 more

5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase

Annals of Oncology(2022)10.1016/j.annonc.2022.01.068
N/A
0DataRank · unranked
3 citations

E. Lee, Ezra Y. Rosen, David R. Spigel, Martin Højgaard, S. Lheureux +15 more

Mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3104
N/A
0DataRank · unranked
17 citations

Noura J. Choudhury, Alison M. Schram, Ezra Y. Rosen, Yonina R. Murciano‐Goroff, Christina J. Falcon +13 more

Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12100
N/A
0DataRank · unranked
2 citations

Alexander Pan, George Dranitsaris, Ucalene Harris, Sarat Chandarlapaty, Chau T. Dang +11 more

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3135
N/A
0DataRank · unranked
0 citations

Yonina R. Murciano‐Goroff, Justin Jee, Maria E. Arcila, Darren J. Buonocore, Jianjiong Gao +15 more

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

Journal of Clinical Oncology(2023)10.1200/jco.23.00561
N/A
0DataRank · unranked
44 citations

Antonio Marra, Binbin Zheng-Lin, Pier Selenica, Juan Blanco-Heredia, Yingjie Zhu +30 more

EZH2 inhibition: it’s all about the context

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad141
N/A
0DataRank · unranked
4 citations

Neerav Shukla, Julia Glade Bender, Ezra Y. Rosen

Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0154
N/A
0DataRank · unranked
9 citations

S. K. Sinha, Ardijana Novaj, Jennifer Ma, Niamh McDermott, Xin Pei +16 more

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3981
N/A
0DataRank · unranked
12 citations

Soo‐Ryum Yang, Jessica J. Tao, Antoine Desîlets, Eli L. Diamond, Clare Wilhelm +18 more

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.05.08.593195
N/A
0DataRank · unranked
2 citations

Malvika Sharma, M. Dorso, Nicholas Mai, Corina Amor, Jason Reiter +21 more

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2424286122
N/A
0DataRank · unranked
9 citations

Ezra Y. Rosen, Malvika Sharma, M. Dorso, Nicholas Mai, Corina Amor +22 more